Business Context and Reporting Period
The filing is Landec Corporation’s Form 10-Q for the three months ended August 30, 2015, the first quarter of fiscal 2016. The submitted metadata identifies Lifecore Biomedical, Inc., but the registrant in the filing is Landec Corporation, whose subsidiaries include Lifecore Biomedical and Apio, Inc.
Landec operates three principal businesses: Packaged Fresh Vegetables, Food Export, and Biomaterials. Lifecore comprises the Biomaterials segment and sells hyaluronan and non-hyaluronan products and services primarily for ophthalmic, orthopedic, and veterinary applications.
The current quarter had 13 weeks, compared with 14 weeks in the prior-year comparable quarter, which affects year-over-year comparisons.
Key Financial Metrics
| Metric | Q1 FY2016 | Q1 FY2015 | Change |
|---|---|---|---|
| Revenue | $135.4 million | $133.6 million | 1% |
| Gross profit | $18.0 million | $14.2 million | 27% |
| Gross margin | 13.3% | 10.6% | Up 2.7 points |
| Operating income | $3.9 million | $3.5 million | 11% |
| Operating margin | 2.9% | 2.6% | Up 0.3 points |
| Net income attributable to common stockholders | $3.0 million | $2.4 million | 25% |
| Net margin | 2.2% | 1.8% | Up 0.4 points |
| Diluted earnings per share | $0.11 | $0.09 | Increase |
| Cash flow from operations | $(1.8) million | $3.9 million | Decrease |
| Capital expenditures | $3.5 million | $4.1 million | Decrease |
- Packaged Fresh Vegetables revenue increased 4% to $103.7 million, supported by higher-priced salad kit products and favorable product mix.
- Food Export revenue decreased 16% to $22.3 million, primarily because unit volume declined 15% amid the stronger U.S. dollar.
- Biomaterials revenue increased 29% to $8.8 million, driven by higher development-service revenue and recovery of fermentation orders from a key customer.
- Gross profit benefited from favorable mix in the packaged vegetable and Biomaterials businesses. Biomaterials gross profit increased to $3.2 million from $1.0 million.
- Research and development expense increased 4% to $1.9 million. Selling, general and administrative expense increased 37% to $12.2 million, primarily due to Apio product launches, advertising, promotions, added personnel, and higher stock-based compensation.
- Dividend income from the Windset investment was $413,000, and the increase in Windset’s estimated fair value generated $800,000 of other income.
- Total debt was $40.6 million, including $7.7 million classified as current. Cash and cash equivalents were $7.1 million at August 30, 2015, down from $14.1 million at May 31, 2015.
- Apio had $24.7 million of availability under its revolving credit facility, and Lifecore had $8.5 million of availability under its working-capital facility. No amounts were outstanding under either facility at quarter-end.
- Landec reported compliance with all applicable debt covenants.
Material Changes Versus the Prior Comparable Period
- Revenue grew modestly despite the shorter current-year quarter, as packaged vegetable and Biomaterials growth offset the Food Export decline.
- Profitability improved materially because of higher-margin product and service mix, particularly in Biomaterials and new packaged salad products.
- Operating expenses rose substantially, including a $3.3 million increase in SG&A. The prior-year quarter benefited from a $677,000 reversal of accrued long-term incentive plan expense, making the current-year comparison less favorable.
- Operating cash flow shifted from a $3.9 million inflow to a $1.8 million outflow. Key uses included a $3.4 million inventory increase, lower accounts payable, payment of fiscal 2015 bonuses, and payment of income taxes.
- Investing cash use declined to $3.4 million from $15.1 million because the prior-year period included an $11.0 million additional investment in Windset.
- Financing cash flow changed from a $5.4 million inflow to a $1.8 million outflow, primarily reflecting $1.9 million of debt repayments in the current quarter.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that cash from operations, existing cash, cash equivalents, and marketable securities should be sufficient to fund operating and capital requirements for at least the next twelve months. The filing does not provide specific earnings or revenue guidance.
- Management expects seasonality in Apio’s food and export businesses and fluctuations in Lifecore customer ordering patterns; quarterly results may therefore not indicate full-year performance.
- The Windset investment was valued at $62.3 million using a Level 3 discounted cash flow model. Its valuation is sensitive to assumptions including revenue growth, expense growth, and discount rates.
- Customer concentration is significant: the top five customers represented 47% of revenue, while Costco and Walmart represented 20% and 11%, respectively.
- Foreign exchange exposure affected Food Export results, as the stronger U.S. dollar made products more expensive for Asian customers.
- Debt agreements are secured by liens on subsidiary assets and contain customary restrictions and financial covenants. Landec guarantees certain Apio and BofA obligations and has pledged its equity interest in Apio under the revolving credit agreement.
- On September 4, 2015, Lifecore entered into a seven-year lease for a 65,000-square-foot facility. The lease is expected to be accounted for as a capital lease with an initial asset and liability of approximately $3.8 million and monthly expense of approximately $38,000.
- On September 28, 2015, Apio borrowed $1.3 million under its equipment financing commitment to support capacity expansion. The draw was expected to be refinanced into a fixed-rate equipment term loan around April 2016.
- The company reported no significant legal proceedings, no significant changes to previously disclosed risk factors, and effective disclosure controls.
Important Facts for Investors to Verify
- Confirm that the intended issuer is Landec Corporation rather than Lifecore Biomedical, Inc., based on the filing’s registrant information.
- Assess whether the improved gross margin is sustainable after accounting for product mix, salad-kit launches, and Biomaterials development-service revenue.
- Monitor operating cash conversion, inventory growth, working-capital requirements, and the effect of planned capital expenditures.
- Review Windset’s Level 3 valuation, dividend and put/call arrangements, and sensitivity to changes in valuation assumptions.
- Evaluate customer concentration, foreign exchange exposure, and the impact of the shorter current-year quarter on comparisons.
- Track debt repayments, covenant headroom, new equipment financing, and the financial effect of Lifecore’s new facility lease.